MICHAEL MOLHOJ,JOERG MOELLEKEN,JOERG THOMAS REGULA,HUBERT KETTENBERGER,GUY GEORGES,PETER MICHAEL HUELSMANN,STEFAN DENGL
申请号：
ARP150103648
公开号：
AR102595A1
申请日:
2015.11.09
申请国别(地区):
AR
年份:
2017
代理人:
摘要：
11. Claim 1: an antibody specifically combined with Ang2 person, wherein the antibody comprises: (a) a rhv-h1 containing a single amino acid sequence ID 20, (b) a rhv-h2 containing a single amino acid sequence ID 21, (c) a rhv-h3 containing a single amino acid sequence ID 23. Claim 5: an antibody specifically related to Ang2, wherein the antibody: (I) comprises a heavy chain variable domain, the amino acid sequence number of which is sec ID 19, more than 70%, and the light chain variable domain, the sequence number of which is sec ID 6, more than 70%,ii) it presents in the heavy chain variable domain at position 28 the amino acid residue asparagine (N),At position 30, the residual amino acid A (a),In the position of 100b residual amino acid (P) and 100J residual amino acid (a), and in the light chain variable domain 51 residual amino acid (T) (Kabat No.)and iii) the antibody has a lower EC₅₀ value for inhibition of binding of ANG2 to its Tie2 receptor in a cell assay using HEK293 cells stably expressing human Tie2 determined using a Tie2 phosphorylation ELISA compared to an antibody comprising a heavy chain variable domain presenting the SEC sequenceIbid., No. 19 and a light chain variable field that shows sec number 6 or SEC number 33. Claim 10: pharmaceutical preparations containing antibodies contained in any one of the 1 to 9 claims, or an alternative acceptable pharmaceutical holder. D. Claim 14: use of any claim 12 and 13The aim of the drug is to treat ocular vascular diseases, preferably nodal degeneration. Claim 15: in claims 12 and 13, the use of any one claim is for the treatment of cancer, preferably new angioplasty cancer.Reivindicación 1: Un anticuerpo que se une específicamente a ANG2 humano, en el que el anticuerpo comprende: (a) un RHV-H1 que comprende la secuencia de aminoácidos SEC ID nº 20, (b) un RHV-H2 que comprende la secuencia de aminoácidos SEC ID nº 21, y (c) un RHV-H3 que comprende la secuencia de aminoácidos SEC ID nº 23. Reivindicación 5:
